Welt Aims to Evolve from Sleep Therapy to AI-Powered Medication Management Platform
Personalizing Medication Timing Through Patient Condition Analysis
"Growing as a Platform Company Combining AI and Pharmaceuticals"
Welt, a digital therapeutics (DTx) company, has announced plans to expand its business from its digital insomnia treatment device "SleepQ" into an artificial intelligence (AI)-based medication management platform. The company aims to develop a platform that personalizes medication timing based on data accumulated from sleep therapy and to accelerate its entry into the global market.
Kang Sungji, CEO of Welt, is presenting the future development plans and growth strategy for the digital insomnia treatment device 'SleepQ' at a media briefing held on the 10th at Welt headquarters in Gangnam-gu, Seoul. Welt.
View original imageAt a media briefing held on March 10 at Welt headquarters in Gangnam-gu, Seoul, CEO Sungji Kang stated, "While SleepQ 1.0 implemented the treatment process previously carried out by humans into an algorithm, version 2.0 will evolve that algorithm into an AI-based agent. It will continuously analyze the patient's condition and guide them on exactly when to take their medication," he explained.
SleepQ is a smartphone application-based digital therapeutic device that delivers cognitive behavioral therapy (CBT) in digital form. It is available by prescription from medical professionals, and patients use it over a six-week period to improve sleep habits through sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, and sleep hygiene education. In collaboration with its partner, Handok’s prescription drug sales team, SleepQ is currently prescribed at more than 20 general hospitals and 60 clinics. SleepQ received approval from the Ministry of Food and Drug Safety in 2023 as the first innovative medical device under the integrated review system.
SleepQ is one example of the "Drug OS" platform that Welt is envisioning. CEO Kang explained, "While maintaining the structure in which physicians retain prescribing authority, we are introducing artificial intelligence between the patient and the medication to optimize the treatment process. We selected sleep disorders as the first application area because the risk to patients is relatively low in the event of an AI error." He added, "After validating the technological reliability with SleepQ, we plan to expand into other disease areas such as eating disorders."
This year, Welt plans to accelerate its domestic and international market expansion with SleepQ as its foundation. Clinical trials for adult insomnia patients are currently underway at Charite Hospital in Germany, with plans to launch the product locally within the year. CEO Kang said, "Germany is the most mature market in terms of systems and insurance coverage for digital therapeutics," adding, "We are also exploring opportunities in the Middle Eastern market, including the United Arab Emirates."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Welt also plans to work with Handok and other pharmaceutical companies to pursue a model that combines digital technology with existing pharmaceuticals. CEO Kang stated, "We aim to become the platform company that can most readily apply AI technology to the pharmaceutical industry. By collaborating with pharmaceutical companies, we will create new types of treatment models that combine digital technology with conventional pharmacotherapy."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.